German BRAND Pharmaceutical Issuers Successfully Raise IDR 81 Billion Profit In Three Months In Indonesia

JAKARTA – A business entity engaged in the pharmaceutical and science industry is PT Merck Tbk. it is said that it has managed to record a net profit of Rp. 81 billion in the first quarter of 2022. The book is up 18 percent year on year (yoy) compared to the first quarter of 2021 with a value of Rp. 69 billion.

Merck President Director Evie Yulin said that the slick performance at the beginning of this year could not be separated from revenue growth to IDR 302 billion, or an increase of 19 percent yoy from the previous IDR 253 billion in early 2021.

"The company is optimistic that in the 2022 financial year it can maintain a positive performance to support the progress of stakeholders," he told reporters online on Wednesday, May 25.

Furthermore, Evie explained that the company's total assets, liabilities and equity in the first quarter of 2022 were recorded at IDR 1,066 billion, IDR 314 billion and IDR 753 billion with growth of 4 percent, 8 percent and 10 percent respectively compared to the closing in December 2021.

"We strongly believe that the digitalization foundation that has been developed by the company is getting stronger, and will support the achievement of growth targets above the market, and are determined to focus on efforts to develop the private sector," he said.

For information, the company coded as a MERK issuer focuses its business on the medicinal raw material (BBO) business line which is a residual from the chemical business owned by Merck KGaA as Principal in Germany.

This division showed a positive performance in 2021 with a 21 percent growth to Rp94 billion from the previous Rp78 billion in 2020.

However, the contribution of BBO to the company's total revenue decreased, from 12 percent in 2020 to 9 percent in 2021 because the company focused on increasing its healthcare business and export activities.